Strides Pharma Science (NSE:STAR) Long-Term Debt: ₹5,523 Mil (As of Mar. 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
70 GF Score
Price ₹1,128.20
GF Value ₹777.97
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Long-Term Debt?

Strides Pharma Science NSE:STAR +0.59% 70 Long-Term Debt is ₹5,523 Mil as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 70/100 and a GF Value™ of ₹777.97 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Strides Pharma Science's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹5,523 Mil.

Strides Pharma Science's quarterly Long-Term Debt declined from Sep. 2025 (₹4,930 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹5,523 Mil).

Strides Pharma Science's annual Long-Term Debt declined from Mar. 2024 (₹6,715 Mil) to Mar. 2025 (₹5,712 Mil) and declined from Mar. 2025 (₹5,712 Mil) to Mar. 2026 (₹5,523 Mil).

Strides Pharma Science  (NSE:STAR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Strides Pharma Science Long-Term Debt Related Terms

Strides Pharma Science Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Long-Term Debt Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,356.23 11,397.92 6,714.99 5,712.44 5,523.16

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,712.44 0.00 4,930.12 0.00 5,523.16
NSE:STAR
70GF Score
Strides Pharma Science Ltd NSE:STAR
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹5,523 Mil mean?
Strides Pharma Science (NSE:STAR) has a Long-Term Debt of ₹5,523 Mil as of Mar. 2026.
Is Strides Pharma Science's Long-Term Debt too high?
Strides Pharma Science's current Long-Term Debt is ₹5,523 Mil. Overall, Strides Pharma Science has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Long-Term Debt compare to ZTS and UTHR?
Strides Pharma Science's Long-Term Debt of ₹5,523 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Strides Pharma Science's current Long-Term Debt is ₹5,523 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹777.97, compared to a current price of ₹1,128.20 — trading 45% above its estimated fair value. The current Long-Term Debt is ₹5,523 Mil. Strides Pharma Science's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Long-Term Debt is ₹5,523 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,128.20 is trading 45% above its estimated GF Value™ of ₹777.97. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Long-Term Debt: ₹5,523 Mil
  • GF Value™: ₹777.97 vs. price of ₹1,128.20 (45% above fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
70GF Score

Get the complete analysis for NSE:STAR

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,128.20
Price
₹777.97
GF Value